[go: up one dir, main page]

PE20121481A1 - Formulacion de liberacion sostenida - Google Patents

Formulacion de liberacion sostenida

Info

Publication number
PE20121481A1
PE20121481A1 PE2012000862A PE2012000862A PE20121481A1 PE 20121481 A1 PE20121481 A1 PE 20121481A1 PE 2012000862 A PE2012000862 A PE 2012000862A PE 2012000862 A PE2012000862 A PE 2012000862A PE 20121481 A1 PE20121481 A1 PE 20121481A1
Authority
PE
Peru
Prior art keywords
sustained release
release formulation
refers
glycolic acid
formulation
Prior art date
Application number
PE2012000862A
Other languages
English (en)
Inventor
Tomomichi Futo
Seitaro Mizukami
Naoyuki Murata
Hikaru Taira
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20121481A1 publication Critical patent/PE20121481A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA FORMULACION DE LIBERACION SOSTENIDA QUE COMPRENDE: A) UN COMPUESTO DERIVADO DE METASTINA DE FORMULA (I) QUE ES Ac-D-Tyr-Hyp-Asn-Thr-Phe-AzaGly-Leu-Arg(Me)-Trp-NH2 O UNA SAL DEL MISMO; Y B) UN COPOLIMERO DE ACIDO LACTICO-ACIDO GLICOLICO QUE TIENE UN PESO MOLECULAR DE 5000 A 40000, EN DONDE EL CONTENIDO DEL ACIDO GLICOLICO ES DE 0% A 60% EN PESO. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION. DICHA FORMULACION ES UN AGENTE PARENTERAL UTIL EN EL TRATAMIENTO DE CANCER
PE2012000862A 2009-12-22 2010-12-21 Formulacion de liberacion sostenida PE20121481A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009290364 2009-12-22
JP2010144793 2010-06-25

Publications (1)

Publication Number Publication Date
PE20121481A1 true PE20121481A1 (es) 2012-11-12

Family

ID=43743497

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000862A PE20121481A1 (es) 2009-12-22 2010-12-21 Formulacion de liberacion sostenida

Country Status (27)

Country Link
US (2) US20120302508A1 (es)
EP (1) EP2515878B1 (es)
JP (3) JP2013514968A (es)
KR (1) KR20120098906A (es)
CN (2) CN107412725A (es)
AR (1) AR079657A1 (es)
AU (1) AU2010336168A1 (es)
BR (1) BR112012014947A2 (es)
CA (1) CA2785021C (es)
CO (1) CO6551752A2 (es)
CR (1) CR20120290A (es)
DO (1) DOP2012000171A (es)
EA (1) EA020865B1 (es)
EC (1) ECSP12011992A (es)
ES (1) ES2434315T3 (es)
IL (1) IL219967A0 (es)
MA (1) MA33910B1 (es)
MX (1) MX2012006441A (es)
NZ (1) NZ600157A (es)
PE (1) PE20121481A1 (es)
PH (1) PH12012501255A1 (es)
SG (1) SG181436A1 (es)
TN (1) TN2012000255A1 (es)
TW (1) TW201125575A (es)
UY (1) UY33127A (es)
WO (1) WO2011078394A2 (es)
ZA (1) ZA201203775B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012032544A2 (pt) * 2010-06-25 2016-10-11 Takeda Pharmaceutical formulação de liberação prolongada, uso de um composto, e, método para produzir a formulação de liberação prolongada.
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
TWI855377B (zh) 2016-09-30 2024-09-11 瑞士商麥歐文科學有限公司 治療女性不孕症之方法
WO2022163966A1 (ko) * 2021-01-29 2022-08-04 주식회사 티온랩테라퓨틱스 초기 방출 제어된 데포 조성물 및 이의 제조방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
US20030026844A1 (en) * 2000-04-18 2003-02-06 Hee-Yong Lee Injectable sustained release pharmaceutical composition and processes for preparing the same
AR023940A1 (es) * 2000-05-03 2002-09-04 Eriochem Sa Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua
ATE506942T1 (de) * 2000-09-01 2011-05-15 Palmaya Pty Ltd Pharmazeutische zubereitung und methode diese zu verabreichen
EP1346722B1 (en) * 2000-12-01 2008-12-10 Takeda Pharmaceutical Company Limited Method for producing preparation containing bioactive substance
WO2002085399A1 (fr) * 2001-04-20 2002-10-31 Takeda Chemical Industries, Ltd. Preparations contenant un peptide
JP2003002841A (ja) * 2001-04-20 2003-01-08 Takeda Chem Ind Ltd ペプチド含有製剤
CA2511858A1 (en) * 2002-12-26 2004-07-29 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
JP4346650B2 (ja) 2004-06-25 2009-10-21 武田薬品工業株式会社 メタスチン誘導体およびその用途
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
CN1923284A (zh) * 2005-08-30 2007-03-07 孔庆忠 抗癌药物缓释注射剂及其应用
US8404643B2 (en) * 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
TWI386417B (zh) * 2005-12-22 2013-02-21 Takeda Pharmaceutical 轉移抑素衍生物及其用途
ZA200805393B (en) * 2005-12-22 2009-12-30 Takeda Pharmaceutical Metastin derivatives and use thereof
GEP20125597B (en) * 2006-12-18 2012-08-10 Takeda Pharmaceutical Sustained-release composition and production method thereof
US20110118172A1 (en) * 2008-04-24 2011-05-19 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
PE20110939A1 (es) * 2008-12-29 2012-01-19 Takeda Pharmaceutical Agente preventivo/terapeutico contra el cancer
SI2603600T1 (sl) * 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli

Also Published As

Publication number Publication date
CA2785021C (en) 2019-03-05
EA201290372A1 (ru) 2012-12-28
BR112012014947A2 (pt) 2019-09-24
US20180228732A1 (en) 2018-08-16
CR20120290A (es) 2012-09-06
EP2515878B1 (en) 2013-10-30
JP6472730B2 (ja) 2019-02-20
CN107412725A (zh) 2017-12-01
ZA201203775B (en) 2013-08-28
EA020865B1 (ru) 2015-02-27
ECSP12011992A (es) 2012-07-31
CN102665690A (zh) 2012-09-12
CO6551752A2 (es) 2012-10-31
AU2010336168A1 (en) 2012-06-14
KR20120098906A (ko) 2012-09-05
ES2434315T3 (es) 2013-12-16
AR079657A1 (es) 2012-02-08
TW201125575A (en) 2011-08-01
CA2785021A1 (en) 2011-06-30
JP2017160201A (ja) 2017-09-14
MX2012006441A (es) 2012-06-28
IL219967A0 (en) 2012-07-31
EP2515878A2 (en) 2012-10-31
NZ600157A (en) 2013-07-26
US20120302508A1 (en) 2012-11-29
WO2011078394A2 (en) 2011-06-30
UY33127A (es) 2011-07-29
TN2012000255A1 (en) 2013-12-12
WO2011078394A3 (en) 2012-03-15
MA33910B1 (fr) 2013-01-02
JP2016029045A (ja) 2016-03-03
PH12012501255A1 (en) 2012-11-05
DOP2012000171A (es) 2012-08-31
SG181436A1 (en) 2012-07-30
JP2013514968A (ja) 2013-05-02

Similar Documents

Publication Publication Date Title
GT201200332A (es) Composiciones sòlidas
CU24573B1 (es) Ácidos carboxílicos de benzimidazoles y 4-aza, 5-aza, 7-aza y 4,7-diaza-benzimidazoles como agonistas receptores de glp-1, útiles para tratar o prevenir enfermedades cardiometabólicas
EA201290482A1 (ru) Стабильные составы для лиофилизации терапевтических частиц
UA105229C2 (uk) Фармацевтичний склад
EA201201648A1 (ru) Стимуляторы sgc
EA201501033A1 (ru) Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
CY1118362T1 (el) Ανταγωνιστες υποδοχεων cgrp αζαϊνδανιου καρβοξαμιδιου πιπεριδινονης
MY198204A (en) Cyclic Boronic Acid Ester Derivatives And Therapeutic Uses Thereof
NZ629996A (en) 2’- substituted carba-nucleoside analogs for antiviral treatment
MX2016005668A (es) Formas cristalinas de compuestos terapeuticos y sus usos.
SV2011003907A (es) Composiciones antimicrobianas
EP4327874A3 (en) 3,6-disubstituted xanthylium salts
MX376192B (es) Articulo moldeado por inyeccion.
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
CR20110209A (es) Composición farmacéutica sólida
EA201792597A3 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
AR077139A1 (es) Composiciones farmaceuticas utiles para tratar el vch
PE20130728A1 (es) Complejo obtenido a partir de mezclas de acido hialuronico o una sal del mismo y sulfato de condroitina
PE20121481A1 (es) Formulacion de liberacion sostenida
BR112012013918A2 (pt) inibidores de diacil glicerol acil transferase
UY32408A (es) Macrolido anti-inflamatorio
BR112013001462B8 (pt) Composições
IN2012DN00763A (es)
ECSP11010856A (es) Composición farmacéutica sólida
NZ603783A (en) Pharmaceutical aqueous compositions comprising lipoic acid as an antioxidant

Legal Events

Date Code Title Description
FD Application declared void or lapsed